Experimental combo targets tough cancers in early trial
NCT ID NCT05954871
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested an experimental drug called GDC-1971 combined with either osimertinib (for lung cancer) or cetuximab (for colorectal cancer) in 10 people with advanced cancers that had spread. The main goal was to check safety and find the right dose. Researchers also looked at how the drug moves through the body and whether tumors shrank.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GDC-1971 (an experimental drug) combined with either osimertinib or cetuximab
What this could lead to
If successful, this could point toward a new treatment option for people with advanced lung or colorectal cancer who have not responded to other therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 10 participants, focused on safety and dosing. It is not designed to prove effectiveness, and many early-stage drugs do not advance.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
-
Border Medical Oncology
Wodonga, New South Wales, 3690, Australia
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
START South Texas Accelerated Research Therapeutics-San Antonio
San Antonio, Texas, 78229, United States
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
St Vincent's Hospital Melbourne
Fitzroy, Victoria, 3065, Australia